Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 7/20 | 0.52 |
| ▸ | IDO1 | P14902 | 2/20 | 0.45 |
| ▸ | TGM2 | P21980 | 2/20 | 0.44 |
| ▸ | MAPK3 | P27361 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.41 |
| ▸ | JAK3 | P52333 | 1/20 | 0.41 |
| ▸ | FYN | P06241 | 1/20 | 0.40 |
| ▸ | SRC | P12931 | 1/20 | 0.40 |
| ▸ | VCP | P55072 | 1/20 | 0.40 |
| ▸ | BRD4 | O60885 | 1/20 | 0.40 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.40 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.40 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.40 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31097853 | 0.88 | EGFR (0.50) | EGFRMAPK3JAK3SRC | |
| SCHEMBL25311938 | 0.88 | EGFR (0.50) | EGFRMAPK3JAK3SRC | |
| SCHEMBL31097790 | 0.84 | EGFR (0.53) | EGFRMAPK3MAPTALDH1A1KMT2A | |
| SCHEMBL25312624 | 0.84 | EGFR (0.53) | EGFRMAPK3MAPTALDH1A1KMT2A | |
| SCHEMBL25311865 | 0.82 | EGFR (0.51) | EGFRMAPK3MAPTALDH1A1KMT2A | |
| SCHEMBL31097830 | 0.82 | EGFR (0.51) | EGFRMAPK3MAPTALDH1A1KMT2A | |
| SCHEMBL25877036 | 0.81 | EGFR (0.54) | EGFRTGM2MAPK3 | |
| SCHEMBL29074796 | 0.78 | EGFR (0.48) | EGFRIDO1TGM2MAPK3MAPT | |
| SCHEMBL23336267 | 0.77 | EGFR (0.58) | EGFRTGM2MAPK3MAPTLMNA | |
| SCHEMBL29074768 | 0.76 | MAPT (0.44) | EGFRMAPTALDH1A1MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250074889-A1 | Novel Aminobenzene Derivative Having Cancer Cell Growth Inhibitory Effect, and Preventive or Therapeutic Pharmaceutical Composition Containing Same as Active Ingredient | DAEWOONG PHARMACEUTICAL CO., LTD. (KR) | 2025-03-06 | — | — | US | claimed |
| EP-4464693-A1 | NOVEL AMINOBENZENE DERIVATIVE HAVING CANCER CELL GROWTH INHIBITORY EFFECT, AND PREVENTIVE OR THERAPEUTIC PHARMACEUTICAL COMPOSITION CONTAINING SAME AS ACTIVE INGREDIENT | Daewoong Pharmaceutical Co., Ltd. (KR) | 2024-11-20 | — | — | EP | claimed |
| CN-118632836-A | Novel aminobenzene derivative having cancer cell growth inhibitory effect and preventive or therapeutic pharmaceutical composition containing the same as active ingredient | 株式会社大熊制药 | 2024-09-10 | — | — | CN | claimed |
| WO-2023136645-A1 | NOVEL AMINOBENZENE DERIVATIVE HAVING CANCER CELL GROWTH INHIBITORY EFFECT, AND PREVENTIVE OR THERAPEUTIC PHARMACEUTICAL COMPOSITION CONTAINING SAME AS ACTIVE INGREDIENT | 주식회사 대웅제약 | 2023-07-20 | — | — | WO | claimed |
| US-20250074889-A1 | Novel Aminobenzene Derivative Having Cancer Cell Growth Inhibitory Effect, and Preventive or Therapeutic Pharmaceutical Composition Containing Same as Active Ingredient | DAEWOONG PHARMACEUTICAL CO., LTD. (KR) | 2025-03-06 | — | — | US | disclosed |
| EP-4464693-A1 | NOVEL AMINOBENZENE DERIVATIVE HAVING CANCER CELL GROWTH INHIBITORY EFFECT, AND PREVENTIVE OR THERAPEUTIC PHARMACEUTICAL COMPOSITION CONTAINING SAME AS ACTIVE INGREDIENT | Daewoong Pharmaceutical Co., Ltd. (KR) | 2024-11-20 | — | — | EP | disclosed |
| CN-118632836-A | Novel aminobenzene derivative having cancer cell growth inhibitory effect and preventive or therapeutic pharmaceutical composition containing the same as active ingredient | 株式会社大熊制药 | 2024-09-10 | — | — | CN | disclosed |
| WO-2023136645-A1 | NOVEL AMINOBENZENE DERIVATIVE HAVING CANCER CELL GROWTH INHIBITORY EFFECT, AND PREVENTIVE OR THERAPEUTIC PHARMACEUTICAL COMPOSITION CONTAINING SAME AS ACTIVE INGREDIENT | 주식회사 대웅제약 | 2023-07-20 | — | — | WO | disclosed |
| WO-2023136645-A1 | NOVEL AMINOBENZENE DERIVATIVE HAVING CANCER CELL GROWTH INHIBITORY EFFECT, AND PREVENTIVE OR THERAPEUTIC PHARMACEUTICAL COMPOSITION CONTAINING SAME AS ACTIVE INGREDIENT | 주식회사 대웅제약 | 2023-07-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250074889-A1 | Novel Aminobenzene Derivative Having Cancer Cell Growth Inhibitory Effect, and Preventive or Therapeutic Pharmaceutical Composition Containing Same as Active Ingredient | MKI67, CCNB1, ALDH7A1 | EGFR 69/4885IDO1 443/4885TGM2 1550/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.